Immunicum AB publ meddelar kommande konferenser i maj

Immunicum: Videointervju med vd Carlos de Sousa - Redeye

2016-mai 2020 3 år 8 måneder. Stockholm, Sweden Chief 1553 andre med navnet Carlos de Sousa er på LinkedIn Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress. Publicerad: 2020-09-17 (GlobeNewswire) Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med cancerbehandlingar och immunterapier på årets ESMO-kongress Immunicum, VD Carlos de Sousa presenterar på Immunonkologieventet 21 september 25 Sep 2017 04:51 159 0 Carlos de Sousa , companyNid:324160 , eventNid:554288 , Immunicum 13.12.2019 - Press Release 13 December 2019 Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by mutual agreement Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com MEDIERELATIONER. Gretchen Schweitzer och Joanne Tudorica Trophic Communications Telefon: +49 172 861 8540 E-post: ir@immunicum.com U.S.A OCH INTERNATIONELLA INVESTERARE BioStock Life Science Summit 2018 * Carlos de Sousa avgick som VD för Immunicum AB och Alex Karlsson-Parra utsågs till interim VD. * Immunicum meddelade att bolaget går vidare till nästa dosnivå i fas Ib/II kombinationsstudien ILIAD.

Carlos de Sousa is Chief Executive Officer at Immunicum AB. View Carlos de Sousa’s professional profile on Relationship Science, the database of decision makers. Sept 27 (Reuters) - Immunicum AB : * Announces Carlos de Sousa as new CEO * De Sousa will replace Jamal El-Mosleh, Immunicum’s CEO since Sept. 2007, who will now work with de Sousa to assure a Sept 27 (Reuters) - Immunicum AB : * Announces Carlos de Sousa as new CEO * De Sousa will replace Jamal El-Mosleh, Immunicum’s CEO since Sept. 2007, who will now work with de Sousa to assure a Nästan 30 års erfarenhet från roller inom finans och ekonomi från en rad företag inklusive senast Doktor24 Healthcare AB och Medivir AB inom hälsovårds- och life science-sektorn. Under de senaste åren har hon varit finansdirektör samt haft ett flertal positioner som chef för finans- och ekonomiavdelningar. Immunicum AB (publ)| Östermalmstorg 5, 114 42 Stockholm| Tel +4687328 400| Orgnr. 556629-1786|immunicum.se .

3 X Facts – Carlos de Sousa. 01. He is a Medical Doctor by training, having earned his degree at School of Medicine, University of Lisbon, and holds an Executive MBA from the Stern School of Business, New York University.

Biostock vd immunicum intresset är stort hos investerare: 48

Carlos de Sousa ny vd för Immunicum SvD

He is a Medical Doctor by training, having earned his degree at School of Medicine, University of Lisbon, and holds an Executive MBA from the … Immunicum AB (IMMU) okt. 2016-mai 2020 3 år 8 måneder. Stockholm, Sweden Chief Business Officer Zealand 1553 andre med navnet Carlos de Sousa er på LinkedIn Se andre med navnet Carlos de Sousa Carlos’ merke på offentlig profil 2020-02-13 2019-12-13 Carlos De Sousa is Chief Executive Officer at Ultimovacs AS. See Carlos De Sousa's compensation, career history, education, & memberships.

Immunicum AB (publ), First North Premier: (IMMU.ST), ett bioteknikbolag som utvecklar nya immunaktiverande cancerbehandlingar för ett antal solida tumörer, meddelar dag att VD Carlos de Sousa kommer att presentera bolaget samt bakgrunden till bolagets … Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta 2021-03-19 Immunicum: Interview with CEO Carlos de Sousa 2019-10-15 11:20. We have interviewed CEO Carlos de Sousa following the announcement of the complete top-line results from the MERECA study.
If metall oskarshamn

Immunicum baktie. Immunicum AB - The Swedish Life Science — han Immunicum AB - The Swedish Carlos de Sousa, VD för Immunicum. Carlos de Sousa-arkiv - Sida 2 av 2 - BioStock Investera stort arv — VD Immunicum: »Intresset är stort hos internationella investerare« 5: Gå Hey there Carlos de Sousa, CEO of Immunicum Nordic Välkommen till Malmö FF, Carlos Strandberg! Malmö FF carlos | Court1 Frisparkskungen Roberto Carlos Styrelsen för Immunicum meddelade idag att Carlos de Sousa lämnar rollen som verkställande direktör. Carlos de Sousa was appointed CEO of Immunicum in October 2016. Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum New CEO – Carlos de Sousa.

Carlos de Sousa was appointed CEO of Immunicum in October 2016. Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum New CEO – Carlos de Sousa. 08:37; Immunicum today announced the appointment of Carlos de Sousa as Immunicum’s Chief Executive Officer effective on October 1, 2016.Mr. de Sousa brings more than 25 years of relevant experience in the international pharmaceutical and biotech industries, including senior positions at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals Press Release . 13 December 2019. Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO. The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Carlos de Sousa avgår som vd för Immunicum AB (publ) Pressmeddelande. 13 december 2019.
Konservativa partier i europa

Publication date Issuer Person discharging managerial responsibilities Position Closely associated Nature of transaction Instrument name ISIN Transaction date IMMUNICUM AB | 7 followers on LinkedIn | Annan naturvetenskaplig och teknisk forskning och utveckling Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com. Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations . Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledn Carlos de Sousa avgår som vd för Immunicum AB (publ) Pressmeddelande.

Dec . 19 . Corporate Update . Immunicum Article in Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO. by NASDAQ Market News December 13, 2019. Facebook. Twitter.
Rysslands presidenter

fosterstadier veckor
prevodilac srpsko nemacki
trafikverket e20 förbi mariestad
dra husvagn vikt
gsakassa se logga in
lucky star bus

Immunicum AB publ inleder handeln med aktier på Nasdaq

Click here to email author. NEXT STORY Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline.